Xie, Lingling
McDaniel, Miranda J.
Perszyk, Riley E.
Kim, Sukhan
Cappuccio, Gerarda
Shapiro, Kevin A.
Muñoz-Cabello, Beatriz
Sanchez-Lara, Pedro A.
Grand, Katheryn
Zhang, Jing
Nocilla, Kelsey A.
Sheikh, Rehan
Armengol, Lluis
Romano, Roberta
Pierson, Tyler Mark
Yuan, Hongjie http://orcid.org/0000-0002-8127-7145
Myers, Scott J.
Traynelis, Stephen F. http://orcid.org/0000-0002-3750-9615
Funding for this research was provided by:
National Institute of Child Health and Human Development (HD082373)
National Institute of Neurological Disorders and Stroke (NS111619)
National Institute on Aging (AG072142)
Article History
Received: 10 November 2022
Revised: 12 January 2023
Accepted: 20 January 2023
First Online: 31 March 2023
Declarations
:
: SFT is a member of the SAB for Eumentis Therapeutics, Sage Therapeutics, and Combined Brain, is a member of the Medical Advisory Board for the GRIN2B Foundation and the CureGRIN Foundation, is an advisor to GRIN Therapeutics and Neurocrine, is co-founder of NeurOp Inc. and AgriThera Inc., and is a member of the Board of Directors of NeurOp Inc. HY is PI on a research grant from Sage Therapeutics to Emory University School of Medicine. SJM is PI on a research grant from GRIN Therapeutics to Emory University School of Medicine. SFT, SJM, and HY are co-inventors on Emory University-owned Intellectual Property that includes allosteric modulators of NMDA receptor function. TMP has no disclosures.
: This study was approved by the Medical Ethics Committee and the Institutional Review Boards of Federico II University (Italy), University of California, San Francisco (USA), University Hospital Virgen del Rocío (Spain), and Cedars-Sinai Medical Center (USA). All functional studies were performed according to the guidelines of Emory University.